BNT162b2: Clinical Trials

17 trials of BNT162b2, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed, 4 unknown, 1 not yet recruiting, 1 terminated. 17 Phase 2, 3 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 217Completed 11, Unknown 4, Not yet recruiting 1, Terminated 1
Phase 13Completed 2, Unknown 1
Phase 32Completed 2

Follow BNT162b2: new trials by email Literature Review of BNT162b2 trials Research Report on BNT162b2

Trials (filtered) newest first · largest first

All 17 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients
SARS-CoV-2 mRNA Vaccine ARCT-021, Tozinameran, Biospecimen Collection - Hematopoietic and Lymphatic System Neoplasm
Phase 2Not yet recruitingFred Hutchinson Cancer Center562026-12-012026-09-17
COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)
AS03, BNT162b2, BNT162b2 (B.1.1.529) - COVID-19
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)12702022-03-302025-10-20
The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine
BNT162b2, mRNA-1273, MVC-COV1901 - COVID-19, Breakthrough Infection
Phase 1 / Phase 2UnknownChang Gung Memorial Hospital3402021-11-302022-07-25
Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years
BNT162b2 - SARS-CoV-2 Infection, COVID19
Phase 2CompletedBioNTech SE1242021-10-152024-10-09
Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants
BNT162b2, Multivalent BNT162b2 (B.1.1.7 + B.1.617.2), Monovalent BNT162b2 (B.1.1.7) - SARS-CoV-2 Infection, COVID-19
Phase 2CompletedBioNTech SE13802021-08-252024-11-22
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
Moderna mRNA-1273, BNT162b2, Ad26.COV2.S - Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
Phase 2TerminatedNational Institute of Allergy and Infectious Diseases (NIAID)2582021-08-132026-06-10
A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects
BNT162b2s01, BNT162b2 - COVID-19, SARS-CoV-2 Infection
Phase 2CompletedBioNTech SE1372021-07-262024-09-19
Reactogenicity, Safety, and Immunogenicity of Covid-19 Vaccine Booster
Placebo, Inactivated vaccine booster, mRNA vaccine booster - Covid19
Phase 2UnknownUniversidad del Desarrollo5342021-07-082021-08-05
Homologous vs Heterologous Third Vaccination in Kidney Transplant Recipients Kidney Transplant Recipients
Ad26COVS1, ChAdOx1 SARS2 Vaccine, BNT162B2 - COVID-19
Phase 2UnknownMedical University of Vienna2002021-06-152022-04-20
Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity
mRNA-1273 SARS-CoV-2 vaccine, BNT162b2, ChAdOx1-S [recombinant] - COVID-19
Phase 2CompletedCanadian Immunization Research Network6692021-06-112026-11-10
Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines
Ad26.COV2.S, BNT162b2, mRNA-1273 - COVID-19
Phase 1 / Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)8672021-05-282025-04-20
Covid-19 Vaccination in Adolescents and Children
Tozinameran, CoronaVac, CoronaVac, intradermal - Covid19
Phase 2UnknownThe University of Hong Kong10182021-05-082024-01-16
COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations
Moderna COVID-19 Vaccine, Pfizer-BioNTech COVID-19 Vaccine, Placebo - SARS-CoV Infection, COVID-19
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)7462021-04-072025-08-12
To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older
BNT162b2, Placebo - SARS-CoV-2 Infection, COVID-19
Phase 2 / Phase 3CompletedBioNTech SE7262021-02-162024-12-06
Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population
BNT162b2, Placebo - SARS-CoV-2
Phase 2CompletedBioNTech SE9602020-12-042026-03-20
Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
BNT162b1, BNT162b2, Placebo - SARS-CoV-2 Infection, COVID-19
Phase 2 / Phase 3CompletedBioNTech SE469692020-04-292026-03-25
A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults
BNT162a1, BNT162b1, BNT162b2 - Infections, Respiratory, Virus Diseases
Phase 1 / Phase 2CompletedBioNTech SE5122020-04-232024-07-12

Conditions studied

COVID-19 (16)  ·  Severe Acute Respiratory Syndrome (4)  ·  Coronavirus Infections (3)  ·  RNA Virus Infections (2)  ·  Respiratory Tract Infections (2)  ·  Virus Diseases (2)  ·  Arthritis, Juvenile (1)  ·  Arthritis, Rheumatoid (1)  ·  Autoimmune Diseases (1)  ·  Breakthrough Infections (1)  ·  Dermatomyositis (1)  ·  Disease (1)  ·  Hypersensitivity (1)  ·  Lupus Erythematosus, Systemic (1)  ·  Mastocytosis (1)

Sponsors

BioNTech SE (7)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (4)  ·  Canadian Immunization Research Network (1)  ·  Chang Gung Memorial Hospital (1)  ·  Fred Hutchinson Cancer Center (1)  ·  Medical University of Vienna (1)  ·  The University of Hong Kong (1)  ·  Universidad del Desarrollo (1)

Countries

United States (9)  ·  Germany (5)  ·  Brazil (3)  ·  South Africa (3)  ·  China (2)  ·  Turkey (Türkiye) (2)  ·  Argentina (1)  ·  Austria (1)  ·  Canada (1)  ·  Chile (1)  ·  Mexico (1)  ·  Spain (1)  ·  Taiwan (1)  ·  United Kingdom (1)

Top investigators

Amit Bar-Or, MD, FRCP (1)  ·  Cheng-Hsun Chiu, MD, PhD (1)  ·  Dinesh Khanna, MBBS, MSc (1)  ·  James R. Baker Jr., MD (1)  ·  Joanne Langley (1)  ·  Joshua Hill, MD (1)  ·  Judith A. James, MD, PhD (1)  ·  Kirsten E Lyke, M.D. (1)  ·  Meggan C. Mackay, MD, MS (1)  ·  N. Franklin Atkinson Jr., MD (1)  ·  Natasha Mckerran Ruth, MD (1)  ·  Rebecca S. Gruchalla, MD, PhD (1)  ·  Robert L Atmar, M.D. (1)

Results publications

PMID 39197299, PMID 32785213, PMID 33053279, PMID 33301246, PMID 33524990, PMID 34043894, PMID 34525277, PMID 35081293, PMID 35131133, PMID 35316227, PMID 35472295, PMID 35473709, PMID 35653438, PMID 35739094, PMID 35764637, PMID 35792746, PMID 35798000, PMID 35898343, PMID 36055877, PMID 36120090, PMID 36125366, PMID 36378074, PMID 36399969, PMID 37205592, PMID 37433788, PMID 37527039, PMID 37640860, PMID 37992183, PMID 38012751, PMID 39097927, PMID 39325506, PMID 40237463, PMID 40298376, PMID 40396505, PMID 40930044, PMID 41289027, PMID 41698311

NIH funding

5UM1AI148684-02 (1), 5UM1AI148684-03 (1)